OA Dr. Franz Stoiber, Abteilung für Urologie und Andrologie, Salzkammergut-Klinikum Vöcklabruck, fasst die neuen Daten zum Prostatakarzinom zusammen, darunter positive Ergebnisse mit dem PARP-Inhibitor Olaparib und zur Diagnostik mit 68Ga-PSMA11 PET/CT

Behandelte Abstracts in diesem Video:

Kellokumpu-Lehtinen P-LI et al., A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial. Abstract 5000

https://meetinglibrary.asco.org/record/160543/abstract

Gulley JL et al., Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. Abstract 5006

https://meetinglibrary.asco.org/record/160547/abstract

Fendler W et al., Accuracy of ⁶⁸Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial. Abstract 5001

https://meetinglibrary.asco.org/record/161513/abstract

Clarke N et al., Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial. Abstract 5003

https://meetinglibrary.asco.org/record/160539/abstract

Sternberg C et al., A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC). Abstract 5008

https://meetinglibrary.asco.org/record/161552/abstract

Efstathiou E et al., A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naïve prostate cancer (M0HNPC). Abstract 5002

https://meetinglibrary.asco.org/record/161500/abstract

ASCO Annual Meeting 2018